Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and dermatology, diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services. The company was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.

Revenue projections:

Revenue projections for TORNTPHARM
Revenue projections for TORNTPHARM

With TORNTPHARM's revenues forecasted to be lower than last year's, investors are expected to be cautious. A decline in revenue typically harms the company's bottom line, reducing profitability and making investors less confident about the company's ability to sustain its financial health.

Financial Ratios:

currentRatio 1.12600
forwardPE 48.22393
debtToEquity 85.44200
earningsGrowth -0.21800
revenueGrowth 0.41800
grossMargins 0.75765
operatingMargins 0.20205
trailingEps 64.11000
forwardEps 94.09850

TORNTPHARM's current ratio of 1.126 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, TORNTPHARM can comfortably cover its liabilities, reflecting a strong financial outlook.
TORNTPHARM's high debt-to-equity ratio points to a heavily leveraged company. With more debt than equity, TORNTPHARM may face increased financial risk, especially if its earnings or cash flow come under pressure.
TORNTPHARM's positive gross and operating margins indicate healthy profitability. These margins reflect the company's ability to generate income efficiently from its operations, signaling strong financial performance and effective cost management.
TORNTPHARM's forward EPS surpassing its trailing EPS signals projected growth in profitability, with the company expected to perform better this year. This forecast suggests that TORNTPHARM's earnings will improve compared to the previous financial year, highlighting optimism in its financial outlook.

Price projections:

Price projections for TORNTPHARM
Price projections for TORNTPHARM

TORNTPHARM's price projections have gradually increased over time, indicating that analysts are becoming more optimistic about the company's prospects. This suggests confidence in TORNTPHARM's ability to achieve future growth.

Recommendation changes over time:

Recommendations trend for TORNTPHARM
Recommendations trend for TORNTPHARM


Analysts have maintained a buy bias for Torrent Pharmaceuticals Limited, which could prompt investors to consider the stock as a viable investment. With this positive outlook, Torrent Pharmaceuticals Limited is positioned as an attractive option for those looking to park their money in a stable and potentially lucrative company.